Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
41.96
+0.94 (2.29%)
Sep 3, 2025, 4:01 PM EDT
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
3.61
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
288.53B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Roche Holding AG News
- 6 hours ago - Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) - GlobeNewsWire
- 18 hours ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 4 days ago - Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran - GuruFocus
- 4 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ... - GuruFocus
- 4 days ago - Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension - Business Wire
- 4 days ago - Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension - GlobeNewsWire
- 5 days ago - Analog Devices Chair & CEO Trades $5.09M In Company Stock - Benzinga
- 9 days ago - Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA - GlobeNewsWire